Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$66.30 -2.6%	$62.88	$52.50 ▼ $77.00	$1.47B	0.57	319,965 shs	326,192 shs
ARCT Arcturus Therapeutics	$13.50 -0.3%	$12.79	$8.04 ▼ $25.88	$367.21M	2.27	416,565 shs	278,097 shs
HROW Harrow	$35.89 -0.7%	$30.13	$20.85 ▼ $59.23	$1.33B	0.41	500,180 shs	482,017 shs
MESO Mesoblast	$15.62 +26.6%	$11.32	$5.78 ▼ $22.00	$1.58B	2.39	286,241 shs	2.03 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	-2.56%	+2.06%	+2.54%	-4.20%	+5.27%
ARCT Arcturus Therapeutics	-0.30%	-2.03%	+9.31%	+28.21%	-44.40%
HROW Harrow	-0.69%	+2.75%	+13.86%	+49.60%	+42.70%
MESO Mesoblast	+26.58%	+40.59%	+33.62%	+45.71%	+111.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	3.7695 of 5 stars	2.5	1.0	3.3	2.7	3.3	1.3
ARCT Arcturus Therapeutics	1.9703 of 5 stars	3.6	0.0	0.0	1.9	2.5	0.6
HROW Harrow	2.3876 of 5 stars	3.5	1.0	0.0	2.4	2.5	0.6
MESO Mesoblast	1.6949 of 5 stars	2.5	3.0	0.0	2.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.00	Buy	$78.88	18.97% Upside
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	300.00% Upside
HROW Harrow	3.00	Buy	$63.83	77.86% Upside
MESO Mesoblast	3.00	Buy	$18.00	15.24% Upside

Current Analyst Ratings Breakdown

Latest ARCT, MESO, ANIP, and HROW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	MESO Mesoblast	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/11/2025	HROW Harrow	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$76.00
7/10/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$84.00
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/12/2025	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$62.00
6/10/2025	HROW Harrow	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$614.38M	2.34	$7.40 per share	8.96	$19.11 per share	3.47
ARCT Arcturus Therapeutics	$152.31M	2.40	N/A	N/A	$8.90 per share	1.52
HROW Harrow	$199.61M	6.60	$0.14 per share	264.30	$1.95 per share	18.41
MESO Mesoblast	$5.67M	352.01	N/A	N/A	$4.21 per share	3.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	-$18.52M	-$1.27	N/A	15.75	N/A	-3.12%	21.35%	7.52%	8/5/2025 (Estimated)
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
HROW Harrow	-$17.48M	-$0.56	N/A	89.73	N/A	-10.19%	-25.01%	-4.27%	8/6/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)

Latest ARCT, MESO, ANIP, and HROW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	HROW Harrow	$0.01	N/A	N/A	N/A	$64.23 million	N/A
8/5/2025	Q2 2025	ANIP ANI Pharmaceuticals	$1.49	N/A	N/A	N/A	$187.18 million	N/A
8/4/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	$1.70	+$0.33	$0.69	$179.75 million	$197.12 million
5/8/2025	Q1 2025	HROW Harrow	$0.02	-$0.38	-$0.40	-$0.50	$57.00 million	$47.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.46	2.66	1.98
ARCT Arcturus Therapeutics	0.06	5.64	5.64
HROW Harrow	2.01	0.91	0.85
MESO Mesoblast	0.22	0.96	0.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
ARCT Arcturus Therapeutics	94.54%
HROW Harrow	72.76%
MESO Mesoblast	1.43%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	11.10%
ARCT Arcturus Therapeutics	16.60%
HROW Harrow	15.16%
MESO Mesoblast	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	19.26 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
HROW Harrow	180	36.69 million	31.12 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable

ARCT, MESO, ANIP, and HROW Headlines

Recent News About These Companies

Mesoblast stock soars after reporting first Ryoncil sales

9 minutes ago | investing.com

Mesoblast (NASDAQ:MESO) Sees Large Volume Increase - Still a Buy?

July 18 at 12:04 PM | marketbeat.com

Mesoblast (NASDAQ:MESO) Cut to Hold at Jefferies Financial Group

July 18 at 8:50 AM | marketbeat.com

Successful Commercial Launch of Ryoncil®

July 17 at 8:38 PM | globenewswire.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?

July 17 at 12:33 PM | marketbeat.com

Summit X LLC Buys 52,508 Shares of Mesoblast Limited (NASDAQ:MESO)

July 16 at 9:01 AM | marketbeat.com

Mesoblast (NASDAQ:MESO) Share Price Crosses Below 200 Day Moving Average - Here's Why

July 10, 2025 | marketbeat.com

Insider Stock Buying Reaches US$205.4m On Mesoblast

July 8, 2025 | finance.yahoo.com

Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade)

July 7, 2025 | seekingalpha.com

Mesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?

July 2, 2025 | marketbeat.com

Mesoblast Shares Surge on FDA Alignment

July 1, 2025 | sharecafe.com.auS

Mesoblast, FDA agree on marketing application for cell therapy

July 1, 2025 | msn.com

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

July 1, 2025 | benzinga.com

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

June 30, 2025 | globenewswire.com

Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil

June 29, 2025 | msn.com

Mesoblast (NASDAQ:MESO) Shares Down 4.2% - Here's What Happened

June 23, 2025 | marketbeat.com

Mesoblast Limited (MSB.AX)

June 22, 2025 | finance.yahoo.com

Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’

June 12, 2025 | msn.com

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

June 11, 2025 | globenewswire.com

Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval

June 10, 2025 | finance.yahoo.com

Which S&P 500 Move Matters?

May 27, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, MESO, ANIP, and HROW Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$66.30 -1.74 (-2.56%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$66.36 +0.06 (+0.08%)

As of 07/18/2025 04:33 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Arcturus Therapeutics NASDAQ:ARCT

$13.50 -0.04 (-0.30%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$13.65 +0.15 (+1.14%)

As of 07/18/2025 07:56 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Harrow NASDAQ:HROW

$35.89 -0.25 (-0.69%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$36.60 +0.70 (+1.96%)

As of 07/18/2025 06:34 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Mesoblast NASDAQ:MESO

$15.62 +3.28 (+26.58%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$15.83 +0.21 (+1.34%)

As of 07/18/2025 07:59 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time